Exoskeleton robotics in China has bifurcated into two increasingly separate markets: clinical rehabilitation systems for paraplegia, stroke, and early-recovery patients; and consumer/outdoor exoskeletons for assisted mobility, occupational lifting, and leisure. Clinical systems — AiDong, AiKang, BearH, BearA, SkyWalker, Siasun Lower-Limb, Lower-Limb Exoskeleton (Vishee), Xiangyu, BES-Pro — operate under NMPA Class II registration and depend on hospital rehabilitation department procurement. Consumer systems — Hypershell Go/X/X-Ultra, UGO, MiBot, KidGo, Kickstart Walk Assist — ship direct to users and classify outside medical device regulation.
Specialized subcategories include upper-limb rehabilitation exoskeletons (ExoMax, ExoMotus, Fit-U, SyReBo Arm Support), hand rehabilitation (handled under the dedicated hand rehab category in adjacent hubs), lumbar and industrial-safety exoskeletons (BES-HV, BES-Ultra, Ant-H1 Pro, Panda Flexible), and whole-body/humanoid-adjacent platforms (Unitree G1/H1, Walker-S) that blur into general humanoid robotics.
Market development is driven by three concurrent trends. First, rehabilitation reimbursement has expanded in flagship Chinese cities, making clinical-grade exoskeleton rentals and bundled rehabilitation programs financially viable. Second, consumer pricing has collapsed — sub-10,000 RMB consumer systems now exist from multiple vendors, opening outdoor recreation and mobility-assist use cases beyond clinical indication. Third, humanoid robotics overlap (the Unitree line, the XPENG Walker-S) is pulling exoskeleton R&D into lower-cost actuators and AI-driven motion control.
See data methodology for how this listing is maintained.